Literature DB >> 15016749

Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?

W Miehsler1, W Reinisch, E Valic, W Osterode, W Tillinger, T Feichtenschlager, J Grisar, K Machold, S Scholz, H Vogelsang, G Novacek.   

Abstract

BACKGROUND: Patients with inflammatory bowel disease (IBD) are thought to be at increased risk of venous thromboembolism (TE). However, the extent of this risk is not known. Furthermore, it is not known if this risk is specific for IBD or if it is shared by other chronic inflammatory diseases or other chronic bowel diseases. AIMS: To compare the risk of TE in patients with IBD, rheumatoid arthritis, and coeliac disease with matched control subjects. PATIENTS AND METHODS: Study subjects answered a questionnaire assessing the history of TE, any cases of which had to be confirmed radiologically. A total of 618 patients with IBD, 243 with rheumatoid arthritis, 207 with coeliac disease, and 707 control subjects were consecutively included. All three patient groups were compared with control subjects matched to the respective group by age and sex.
RESULTS: Thirty eight IBD patients (6.2%) had suffered TE. This was significantly higher compared with the matched control population with only 10 cases reported (1.6%) (p<0.001; odds ratio (OR) 3.6 (95% confidence interval (CI) 1.7-7.8)). Five patients with rheumatoid arthritis (2.1%) had suffered TE compared with six subjects (2.5%) in the control population matched to patients with rheumatoid arthritis (NS; OR 0.7 (95% CI 0.2-2.9)). TE had occurred in two patients with coeliac disease (1%) compared with four subjects (1.9%) in the control population matched to the coeliac disease group (NS; OR 0.4 (95% CI 0.1-2.5)). In 60% of TE cases in the IBD group, at least one IBD specific factor (active disease, stenosis, fistula, abscess) was present at the time TE occurred.
CONCLUSIONS: IBD is a risk factor for TE. It seems that TE is a specific feature of IBD as neither rheumatoid arthritis, another chronic inflammatory disease, nor coeliac disease, another chronic bowel disease, had an increased risk of TE.

Entities:  

Mesh:

Year:  2004        PMID: 15016749      PMCID: PMC1773996          DOI: 10.1136/gut.2003.025411

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  46 in total

1.  Transient changes of serum lipoprotein(a) as an acute phase protein.

Authors:  S Maeda; A Abe; M Seishima; K Makino; A Noma; M Kawade
Journal:  Atherosclerosis       Date:  1989-08       Impact factor: 5.162

2.  Vascular complications of inflammatory bowel disease.

Authors:  R W Talbot; J Heppell; R R Dozois; R W Beart
Journal:  Mayo Clin Proc       Date:  1986-02       Impact factor: 7.616

3.  Sample size calculations for clinical pharmacology studies.

Authors:  P D Stolley; B L Strom
Journal:  Clin Pharmacol Ther       Date:  1986-05       Impact factor: 6.875

Review 4.  Acute inflammation and microthrombosis induced by endotoxin, interleukin-1, and tumor necrosis factor and their implication in gram-negative infection.

Authors:  M I Cybulsky; M K Chan; H Z Movat
Journal:  Lab Invest       Date:  1988-04       Impact factor: 5.662

5.  Anti-cardiolipin antibodies in patients with inflammatory bowel disease.

Authors:  B W Aichbichler; W Petritsch; G A Reicht; H H Wenzl; A J Eherer; T A Hinterleitner; P Auer-Grumbach; G J Krejs
Journal:  Dig Dis Sci       Date:  1999-04       Impact factor: 3.199

6.  Endotoxin-induced microclots in ulcerative colitis and Crohn's disease.

Authors:  L Juhlin; U Krause; W B Shelley
Journal:  Scand J Gastroenterol       Date:  1980       Impact factor: 2.423

7.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.

Authors:  F C Arnett; S M Edworthy; D A Bloch; D J McShane; J F Fries; N S Cooper; L A Healey; S R Kaplan; M H Liang; H S Luthra
Journal:  Arthritis Rheum       Date:  1988-03

8.  Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone use.

Authors:  Lothar A J Heinemann; Michael A Lewis; Anita Assmann; Christine Thiel
Journal:  Contraception       Date:  2002-03       Impact factor: 3.375

9.  Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid.

Authors:  W Wellmann; P C Fink; F Benner; F W Schmidt
Journal:  Gut       Date:  1986-07       Impact factor: 23.059

10.  Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces.

Authors:  E de Jong; R J Porte; E A Knot; J H Verheijen; J Dees
Journal:  Gut       Date:  1989-02       Impact factor: 23.059

View more
  112 in total

1.  IBD: which patients with IBD are at risk of venous thromboembolism?

Authors:  Ioannis E Koutroubakis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06       Impact factor: 46.802

2.  Deep venous thrombosis after surgery for inflammatory bowel disease: is standard dose low molecular weight heparin prophylaxis enough?

Authors:  Marco Scarpa; Fabio Pilon; Vittorio Pengo; Giovanna Romanato; Cesare Ruffolo; Francesca Erroi; Bison Elisa; Mauro Frego; Elena Ossi; Enzo Manzato; Imerio Angriman
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

Review 3.  Hematologic manifestations of celiac disease.

Authors:  Thorvardur R Halfdanarson; Mark R Litzow; Joseph A Murray
Journal:  Blood       Date:  2006-09-14       Impact factor: 22.113

4.  Increased aggregation response of platelets in patients with inflammatory bowel disease.

Authors:  Akira Andoh; Takashi Yoshida; Yuki Yagi; Shigeki Bamba; Kazunori Hata; Tomoyuki Tsujikawa; Katsuyuki Kitoh; Masaya Sasaki; Yoshihide Fujiyama
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 7.527

Review 5.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

Review 6.  Extraintestinal manifestations in inflammatory bowel disease.

Authors:  Silvio Danese; Stefano Semeraro; Alfredo Papa; Italia Roberto; Franco Scaldaferri; Giuseppe Fedeli; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

Review 7.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

8.  Corticosteroid-responsive Cronkhite-Canada syndrome complicated by thrombosis.

Authors:  Joanna E Sampson; Maureen L Harmon; Mary Cushman; Edward L Krawitt
Journal:  Dig Dis Sci       Date:  2007-03-07       Impact factor: 3.199

9.  Assessment of anti-prothrombin antibodies in thrombosis complicating inflammatory bowel diseases.

Authors:  Simone Saibeni; Maria J Etchevers; Dolors Tassies; Julián Panés; Joan C Reverter; Silvio Danese; Josep M Piqué; Savino Bruno; Maurizio Vecchi; Antonio Gasbarrini; Miquel Sans
Journal:  Int J Colorectal Dis       Date:  2013-04-16       Impact factor: 2.571

Review 10.  Venous thrombosis and prothrombotic factors in inflammatory bowel disease.

Authors:  Fernando Magro; João-Bruno Soares; Dália Fernandes
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.